We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Danaher's Stock Offering Proceeds to Fund BioPharma Buyout
Read MoreHide Full Article
Danaher Corporation (DHR - Free Report) announced that it successfully closed the offering of preferred and common shares to the public. The offering announcement was made on Feb 25, 2019.
It is worth noting here that this conglomerate signed an agreement to acquire General Electric Company’s (GE - Free Report) BioPharma business for $21.4 billion on Feb 25. Since then, the company’s shares have increased roughly 3.8%, ending the trading session at $127.77 on Mar 1.
Offering Details
As noted, Danaher issued 12.1 million of common shares — inclusive of 1.1 million shares sold to the underwriters — for $123.00 per share. In addition, 1.65 million of 4.75% Series A mandatory convertible preferred stocks — including 150,000 shares sold to underwriters — were sold at $1,000 per share.
The company secured net proceeds of $1.44 billion from common shares offerings and $1.60 billion from the issuance of preferred stocks. These proceeds are net of discounts and issuance-related costs.
Danaher intends to use proceeds from these issuances to fund the acquisition of the BioPharma business — part of General Electric’s GE Life Sciences business. However, if this acquisition does not materialize, the company might use net proceeds from the offering for funding its general corporate purposes.
The BioPharma buyout — anticipated to be completed in the fourth quarter of 2019 — will be integrated with Danaher’s Life Sciences segment and will complement the company’s biologics workflow solutions. The buyout is anticipated to boost non-GAAP adjusted earnings by 45-50 cents per share in the first year of the completion of the deal.
Zacks Rank and Stocks to Consider
With a market capitalization of approximately $79.5 billion, Danaher currently carries a Zacks Rank #3 (Hold). In the past 30 days, the Zacks Consensus Estimate for earnings has remained unchanged at $4.78 for 2019.
This company’s share price has increased 20.2% in the past three months compared with 12.3% growth recorded by the industry.
Two better-ranked stocks in the industry are Carlisle Companies Incorporated (CSL - Free Report) and United Technologies Corporation . While Carlisle Companies currently sports a Zacks Rank #1 (Strong Buy), United Technologies carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, earnings estimates for 2019 have improved for Carlisle Companies and United Technologies. Further, the earnings surprise in the last reported quarter was positive 30.58% for Carlisle Companies and 29.14% for United Technologies.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
Image: Bigstock
Danaher's Stock Offering Proceeds to Fund BioPharma Buyout
Danaher Corporation (DHR - Free Report) announced that it successfully closed the offering of preferred and common shares to the public. The offering announcement was made on Feb 25, 2019.
It is worth noting here that this conglomerate signed an agreement to acquire General Electric Company’s (GE - Free Report) BioPharma business for $21.4 billion on Feb 25. Since then, the company’s shares have increased roughly 3.8%, ending the trading session at $127.77 on Mar 1.
Offering Details
As noted, Danaher issued 12.1 million of common shares — inclusive of 1.1 million shares sold to the underwriters — for $123.00 per share. In addition, 1.65 million of 4.75% Series A mandatory convertible preferred stocks — including 150,000 shares sold to underwriters — were sold at $1,000 per share.
The company secured net proceeds of $1.44 billion from common shares offerings and $1.60 billion from the issuance of preferred stocks. These proceeds are net of discounts and issuance-related costs.
Danaher intends to use proceeds from these issuances to fund the acquisition of the BioPharma business — part of General Electric’s GE Life Sciences business. However, if this acquisition does not materialize, the company might use net proceeds from the offering for funding its general corporate purposes.
The BioPharma buyout — anticipated to be completed in the fourth quarter of 2019 — will be integrated with Danaher’s Life Sciences segment and will complement the company’s biologics workflow solutions. The buyout is anticipated to boost non-GAAP adjusted earnings by 45-50 cents per share in the first year of the completion of the deal.
Zacks Rank and Stocks to Consider
With a market capitalization of approximately $79.5 billion, Danaher currently carries a Zacks Rank #3 (Hold). In the past 30 days, the Zacks Consensus Estimate for earnings has remained unchanged at $4.78 for 2019.
Danaher Corporation Price and Consensus
Danaher Corporation Price and Consensus | Danaher Corporation Quote
This company’s share price has increased 20.2% in the past three months compared with 12.3% growth recorded by the industry.
Two better-ranked stocks in the industry are Carlisle Companies Incorporated (CSL - Free Report) and United Technologies Corporation . While Carlisle Companies currently sports a Zacks Rank #1 (Strong Buy), United Technologies carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, earnings estimates for 2019 have improved for Carlisle Companies and United Technologies. Further, the earnings surprise in the last reported quarter was positive 30.58% for Carlisle Companies and 29.14% for United Technologies.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?
From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 – 2017, they soared far above the market's +126.3%, reaching +181.9%.
This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.
See Stocks Today >>